3-methyl-4,5,6,7-tetrahydro-2,1-benzisoxazole | 29146-79-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-methyl-4,5,6,7-tetrahydro-2,1-benzisoxazole
• 英文别名: 5-methyl-3,4-tetramethyleneisoxazole；4,5,6,7-tetrahydro-3-methyl<2,1>benzoisoxazole；3-methyl-4,5,6,7-tetrahydro-benzo[c]isoxazole；3-Methyl-4,5,6,7-tetrahydro-2,1-benzoxazole
• CAS: 29146-79-0
• 化学式: C₈H₁₁NO
• 分子量: 137.181
• InChiKey: SWZOLZDCPLLSKU-UHFFFAOYSA-N

物化性质

• 沸点：
  245.5±9.0 °C(Predicted)
• 密度：
  1.067±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-乙酰基环己酮 在 H₁₄[NaP₅W₃₀O₁₁₀] 盐酸羟胺 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以98%的产率得到3-methyl-4,5,6,7-tetrahydro-2,1-benzisoxazole
  参考文献：
  名称：

  Heteropolyacids as Green and Reusable Catalysts for the Synthesis of Isoxazole Derivatives

  摘要：

  Heteropolyanions with different structures, including Keggin, Dawson, Preyssler, mixed addenda, and sandwich types, catalyzed the formation of 1,3-diphenyl-isoxazole from the condensation of 1,3-diphenyl-propane-1,3-dione and hydroxylamine hydrochloride in different solvents and under heating conditions. Our data vividly indicate that H3PW11CuO40 is the catalyst of choice and could catalyze the synthesis of other isoxazole derivatives in high yields and good selectivities.

  DOI：

  10.1080/00397910701651326

文献信息

• [EN] NEW COMPOUNDS AND METHODS<br/>[FR] NOUVEAUX COMPOSÉS ET PROCÉDÉS
  申请人：BENEVOLENTAI BIO LTD

  公开号：WO2020260871A1

  公开（公告）日：2020-12-30

  The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof. The present invention also relates to pharmaceutical compositions comprising the compounds of the invention, and to their use in the treatment or prevention of medical conditions in which inhibition of c-ABL is beneficial. (I)

  本发明涉及式(I)的化合物或其药用可接受的盐、溶剂化合物、水合物、互变异构体、光学异构体、N-氧化物和/或前药。本发明还涉及包括本发明化合物的药物组合物，以及它们在治疗或预防抑制c-ABL有益的医疗状况中的使用。
• [EN] PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF<br/>[FR] DÉRIVATIFS DE PYRIDINESULFONAMIDE POUVANT ÊTRE UTILISÉS COMME MODULATEURS TRAP1 ET LEURS UTILISATIONS
  申请人：AMATHUS THERAPEUTICS INC

  公开号：WO2021188907A1

  公开（公告）日：2021-09-23

  The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as a-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

  本公开提供了化合物的化学式（I）和药学上可接受的盐、溶剂化合物、水合物、多晶型、共晶体、互变异构体、立体异构体、同位素标记化合物以及其前药。所提供的化合物可能是肿瘤坏死因子（"TNF"）受体相关蛋白1（"TRAP1"）调节剂（例如，TRAP1激活剂）。所提供的化合物还可能恢复PTEN诱导的激酶1（"PINK1"）功能丧失情况下的活性。所提供的化合物还可能改善线粒体的健康、功能、质量、数量和/或活性，和/或减少活性氧自由基的产生。所提供的化合物还可能对聚集或错误折叠的蛋白质（如α-突触核蛋白）进行重折叠或溶解。本公开还提供了包括所提供化合物的药物组合物；包括所提供化合物或药物组合物的试剂盒；以及使用所提供的化合物和药物组合物的方法（例如，用于治疗需要的受试者的疾病）。
• Suwinski, J.; Walczak, K., Polish Journal of Chemistry, 1992, vol. 66, # 5, p. 777 - 785
  作者：Suwinski, J.、Walczak, K.

  DOI：——

  日期：——
• Martins, Marcos A. P.; Flores, Alex F. C.; Freitag, Rogerio, Journal of Heterocyclic Chemistry, 1995, vol. 32, # 3, p. 731 - 734
  作者：Martins, Marcos A. P.、Flores, Alex F. C.、Freitag, Rogerio、Zanatta, Nilo

  DOI：——

  日期：——